HIV/AIDS epidemiology, pathogenesis, prevention, and treatment
暂无分享,去创建一个
[1] E. Schouten,et al. Scaling up antiretroviral therapy in Africa: learning from tuberculosis control programmes--the case of Malawi. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[2] Richard A. Lempicki,et al. Identification of Dynamically Distinct Subpopulations of T Lymphocytes That Are Differentially Affected by HIV , 2001, The Journal of experimental medicine.
[3] N. Rollins,et al. Preventing postnatal transmission of HIV-1 through breast-feeding: modifying infant feeding practices. , 2004, Journal of acquired immune deficiency syndromes.
[4] R. Osathanondh,et al. HIV-1 Langerhans' Cell Tropism Associated with Heterosexual Transmission of HIV , 1996, Science.
[5] G. Garnett,et al. The Impact of Migration on HIV-1 Transmission in South Africa: A Study of Migrant and Nonmigrant Men and Their Partners , 2003, Sexually transmitted diseases.
[6] C. M. Owens,et al. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys , 2004, Nature.
[7] J. Schwebke. Abnormal vaginal flora as a biological risk factor for acquisition of HIV infection and sexually transmitted diseases. , 2005, The Journal of infectious diseases.
[8] J. Habbema,et al. Determinants of the impact of sexually transmitted infection treatment on prevention of HIV infection: a synthesis of evidence from the Mwanza, Rakai, and Masaka intervention trials. , 2005, The Journal of infectious diseases.
[9] L. Ferradini,et al. Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up. , 2004, AIDS.
[10] John P. Moore,et al. Inhibiting sexual transmission of HIV-1 infection , 2003, Nature Reviews Microbiology.
[11] Hui Li,et al. Nef-Mediated Suppression of T Cell Activation Was Lost in a Lentiviral Lineage that Gave Rise to HIV-1 , 2006, Cell.
[12] Robin Shattock,et al. In Vitro and In Vivo: The Story of Nonoxynol 9 , 2005, Journal of acquired immune deficiency syndromes.
[13] Bernard Branson,et al. A rapid review of rapid HIV antibody tests , 2006, Current infectious disease reports.
[14] W. Mcfarland,et al. Acceptability of Adult Male Circumcision for Sexually Transmitted Disease and HIV Prevention in Zimbabwe , 2005, Sexually transmitted diseases.
[15] T. Quinn,et al. HIV/AIDS in Women: An Expanding Epidemic , 2005, Science.
[16] S. Louisirirotchanakul,et al. Usage of dried blood spots for molecular diagnosis and monitoring HIV-1 infection. , 2005, Journal of virological methods.
[17] F. Antunes,et al. Post-Exposure Prophylaxis of HIV Infection in Healthcare Workers: Recommendations for the European Setting , 2003, European Journal of Epidemiology.
[18] A. Haase. Perils at mucosal front lines for HIV and SIV and their hosts , 2005, Nature Reviews Immunology.
[19] I. Kleinschmidt,et al. Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey , 2005, AIDS.
[20] F. E. McCutchan,et al. In-Depth Analysis of a Heterosexually Acquired Human Immunodeficiency Virus Type 1 Superinfection: Evolution, Temporal Fluctuation, and Intercompartment Dynamics from the Seronegative Window Period through 30 Months Postinfection , 2005, Journal of Virology.
[21] B. Rovin,et al. The Influence of CCL 3 L 1 Gene – Containing Segmental Duplications on HIV-1 / AIDS Susceptibility , 2009 .
[22] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[23] M. Lederman,et al. HIV long-term non-progressors maintain brisk CD8 T cell responses to other viral antigens , 2002, AIDS.
[24] A. van der Straten,et al. Predictors of Diaphragm Use as a Potential Sexually Transmitted Disease/HIV Prevention Method in Zimbabwe , 2005, Sexually transmitted diseases.
[25] J. T. Boerma,et al. Community effects on the risk of HIV infection in rural Tanzania , 2002, Sexually transmitted infections.
[26] Cohen Ms,et al. Amplified HIV transmission and new approaches to HIV prevention. Editorial commentary. , 2005 .
[27] S. Nisole,et al. TRIM family proteins: retroviral restriction and antiviral defence , 2005, Nature Reviews Microbiology.
[28] D. Jamieson,et al. Integrating family planning and prevention of mother-to-child HIV transmission in resource-limited settings , 2005, The Lancet.
[29] J. Weber,et al. The Development of Vaginal Microbicides for the Prevention of HIV Transmission , 2005, PLoS medicine.
[30] R. Bosch,et al. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression , 2004, AIDS.
[31] D. Richman,et al. HIV superinfection. , 2005, The Journal of infectious diseases.
[32] L. Bekker,et al. Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines , 2004, AIDS.
[33] Christine Hogan,et al. Primary HIV-1 Infection Is Associated with Preferential Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.
[34] S. Shorte,et al. CXCR4-Tropic HIV-1 Envelope Glycoprotein Functions as a Viral Chemokine in Unstimulated Primary CD4+ T Lymphocytes1 , 2004, Journal of Immunology.
[35] M. Emerman,et al. Ancient Adaptive Evolution of the Primate Antiviral DNA-Editing Enzyme APOBEC3G , 2004, PLoS biology.
[36] Emmanuel Lagarde,et al. Randomized, Controlled Intervention Trial of Male Circumcision for Reduction of HIV Infection Risk: The ANRS 1265 Trial , 2005, PLoS medicine.
[37] P. Bieniasz,et al. Late budding domains and host proteins in enveloped virus release. , 2006, Virology.
[38] B. Cullen. Role and Mechanism of Action of the APOBEC3 Family of Antiretroviral Resistance Factors , 2006, Journal of Virology.
[39] K. Mansfield,et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity , 2006, Nature.
[40] Michelle de Souza,et al. Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. , 2005, The Journal of infectious diseases.
[41] Xianghui Yu,et al. Differential Requirement for Conserved Tryptophans in Human Immunodeficiency Virus Type 1 Vif for the Selective Suppression of APOBEC3G and APOBEC3F , 2006, Journal of Virology.
[42] G. Maartens,et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa , 2004, AIDS.
[43] M. Garenne. Male Circumcision and HIV Control in Africa , 2006, PLoS medicine.
[44] P. Kulkarni,et al. Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. , 2003, AIDS reviews.
[45] D. Katzenstein,et al. Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. , 2005, The Journal of infectious diseases.
[46] Jon Cohen,et al. Public health. AIDS vaccine trial produces disappointment and confusion. , 2003, Science.
[47] Reuben S. Harris,et al. Retroviral restriction by APOBEC proteins , 2004, Nature Reviews Immunology.
[48] D. Francis,et al. Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials , 2003, AIDS.
[49] S. Mallal,et al. Antiretroviral-therapy-associated lipoatrophy: current status and future directions. , 2005, Sexual health.
[50] A. Wald,et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. , 2004, The New England journal of medicine.
[51] M. Neuberger,et al. In Vitro Deamination of Cytosine to Uracil in Single-stranded DNA by Apolipoprotein B Editing Complex Catalytic Subunit 1 (APOBEC1)* , 2003, Journal of Biological Chemistry.
[52] A. Winston,et al. The use of a triple nucleoside‐nucleotide regimen for nonoccupational HIV post‐exposure prophylaxis , 2005, HIV medicine.
[53] A. Mocroft,et al. Starting highly active antiretroviral therapy: why, when and response to HAART. , 2004, The Journal of antimicrobial chemotherapy.
[54] S. A. Abdool Karim,et al. Seroprevalence of HIV infection in rural South Africa , 1992, AIDS.
[55] C. Orrell. Antiretroviral adherence in a resource-poor setting , 2005, Current HIV/AIDS reports.
[56] Constance A Nyamukapa,et al. HIV Decline Associated with Behavior Change in Eastern Zimbabwe , 2006, Science.
[57] M. Newell,et al. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. , 2003, Journal of acquired immune deficiency syndromes.
[58] J V Giorgi,et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. , 1999, The Journal of infectious diseases.
[59] D. Harris,et al. Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1-infected children in resource-poor settings , 2003, The Lancet.
[60] Jim Y. Kim,et al. Scaling-up treatment for HIV/AIDS: lessons learned from multidrug-resistant tuberculosis , 2004, The Lancet.
[61] Katharina Kober,et al. Scaling up access to antiretroviral treatment in southern Africa: who will do the job? , 2004, The Lancet.
[62] M. Tremblay,et al. Plunder and Stowaways: Incorporation of Cellular Proteins by Enveloped Viruses , 2005, Journal of Virology.
[63] R. Short,et al. How does male circumcision protect against HIV infection? , 2000, BMJ : British Medical Journal.
[64] T. Quinn,et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.
[65] Joseph Sodroski,et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[66] S. Weller,et al. Condom effectiveness in reducing heterosexual HIV transmission. , 2002, The Cochrane database of systematic reviews.
[67] A. Telenti,et al. HIV-1 co/super-infection in intravenous drug users , 2004, AIDS.
[68] P. Bieniasz,et al. Role of ESCRT-I in Retroviral Budding , 2003, Journal of Virology.
[69] James Curran,et al. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach , 2005 .
[70] A. Telenti,et al. Host genetics of HIV-1 susceptibility , 2006 .
[71] J. Bartlett. Dual HIV-1 infection associated with rapid disease progression , 2004 .
[72] R. Reichman,et al. APOBEC3G/CEM15 (hA3G) mRNA Levels Associate Inversely with Human Immunodeficiency Virus Viremia , 2005, Journal of Virology.
[73] S. Eshleman,et al. Nevirapine resistance after single dose prophylaxis. , 2002, AIDS reviews.
[74] B. Berkhout,et al. Triple HIV-1 infection. , 2005, The New England journal of medicine.
[75] M. Breindl,et al. Transcriptionally active genome regions are preferred targets for retrovirus integration , 1990, Journal of virology.
[76] F. Miedema,et al. T cell dynamics in HIV-1 infection. , 1999, Advances in immunology.
[77] M. Bachmann. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults , 2006, AIDS care.
[78] N. Low,et al. HIV and male circumcision--a systematic review with assessment of the quality of studies. , 2005, The Lancet. Infectious diseases.
[79] D. Ho,et al. Natural Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1 Diversification , 2005, PLoS pathogens.
[80] Alan S. Perelson,et al. Turnover Rates of B Cells, T Cells, and NK Cells in Simian Immunodeficiency Virus-Infected and Uninfected Rhesus Macaques1 , 2003, The Journal of Immunology.
[81] M. Carrington,et al. Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. , 1999, Human molecular genetics.
[82] M. Newell. Current issues in the prevention of mother-to-child transmission of HIV-1 infection. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[83] N. Landau,et al. New insights into the role of Vif in HIV-1 replication. , 2004, AIDS reviews.
[84] P. Bieniasz. Intrinsic immunity: a front-line defense against viral attack , 2004, Nature Immunology.
[85] D. Ho,et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. , 1993, Science.
[86] R. Zachariah,et al. High acceptability of voluntary counselling and HIV‐testing but unacceptable loss to follow up in a prevention of mother‐to‐child HIV transmission programme in rural Malawi: scaling‐up requires a different way of acting , 2005, Tropical medicine & international health : TM & IH.
[87] K. Hertogs,et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. , 2003, The Journal of infectious diseases.
[88] M. Malim,et al. Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins. , 2005, Virology.
[89] F. Behets,et al. Desperately seeking targets: the ethics of routine HIV testing in low-income countries. , 2006, Bulletin of the World Health Organization.
[90] H. Epstein,et al. Concurrent sexual partnerships help to explain Africa's high HIV prevalence: implications for prevention , 2004, The Lancet.
[91] R. Doms,et al. HIV-1 coreceptors and their inhibitors. , 2006, Current topics in microbiology and immunology.
[92] M. Feinberg,et al. Prospects for an AIDS vaccine: three big questions, no easy answers. , 2004, The Lancet. Infectious diseases.
[93] O. Laeyendecker,et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. , 2005, The Journal of infectious diseases.
[94] M. Newell,et al. Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. , 2005, The Cochrane database of systematic reviews.
[95] H. Rees,et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial , 2002, The Lancet.
[96] C. Gilks,et al. Scaling up treatment--why we can't wait. , 2005, The New England journal of medicine.
[97] N. Sewankambo,et al. Population-based study of fertility in women with HIV-1 infection in Uganda , 1998, The Lancet.
[98] E. Vittinghoff,et al. Sexual Risk, Nitrite Inhalant Use, and Lack of Circumcision Associated With HIV Seroconversion in Men Who Have Sex With Men in the United States , 2005, Journal of acquired immune deficiency syndromes.
[99] L. Wain,et al. Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1 , 2006, Science.
[100] W. Cates. Review of Non-hormonal Contraception (Condoms, Intrauterine Devices, Nonoxynol-9 and Combos) on HIV Acquisition , 2005, Journal of acquired immune deficiency syndromes.
[101] G. Boiteau,et al. J. Virol. Methods , 1996, Journal of Virological Methods.
[102] L. Duffy. Culture and Context of HIV Prevention in Rural Zimbabwe: The Influence of Gender Inequality , 2005, Journal of transcultural nursing : official journal of the Transcultural Nursing Society.
[103] A. Kamali,et al. Migration and HIV‐1 seroprevalence in a rural Ugandan population , 1995, AIDS.
[104] O. Yang,et al. Transience of vaccine-induced HIV-1-specific CTL and definition of vaccine "response". , 2006, Vaccine.
[105] L. John,et al. Prevention of Mother-to-Child Transmission of HIV Infection , 2005 .
[106] M. Malim,et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein , 2002, Nature.
[107] Paul Shinn,et al. A role for LEDGF/p75 in targeting HIV DNA integration , 2005, Nature Medicine.
[108] P. Musoke,et al. Persistence of Nevirapine Exposure During the Postpartum Period After Intrapartum Single-Dose Nevirapine in Addition to Zidovudine Prophylaxis for the Prevention of Mother-to-Child Transmission of HIV-1 , 2005, Journal of acquired immune deficiency syndromes.
[109] J. Montaner,et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.
[110] J. Sodroski,et al. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.
[111] J. Callen. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners: de Vincenzi I for the European Study Group on Heterosexual Transmission of HIV. N Engl J Med 1994;331:341–346 , 1995 .
[112] Adeeba Kamarulzaman,et al. AIDS Res Hum Retroviruses , 2006 .
[113] M. Markowitz,et al. The gastrointestinal tract is critical to the pathogenesis of acute HIV-1 infection. , 2005, The Journal of allergy and clinical immunology.
[114] S. Aral,et al. Measuring outcomes of behavioural interventions for STD/HIV prevention , 1996, International journal of STD & AIDS.
[115] Q. A. Karim,et al. The evolving HIV epidemic in South Africa , 2002 .
[116] G. Garnett,et al. A Systematic Review of the Epidemiologic Interactions Between Classic Sexually Transmitted Diseases and HIV: How Much Really Is Known? , 2001, Sexually transmitted diseases.
[117] N. Ford,et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment , 2006, The Lancet.
[118] O. Shisana,et al. Correcting gender inequalities is central to controlling HIV/AIDS. , 2004, Bulletin of the World Health Organization.
[119] J. Schapiro,et al. Antiretroviral Drug Resistance in Non-Subtype B HIV-1, HIV-2 and Siv , 2004, Antiviral therapy.
[120] Sebastian Bonhoeffer,et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis , 1999, The Lancet.
[121] P S Kim,et al. Mechanisms of viral membrane fusion and its inhibition. , 2001, Annual review of biochemistry.
[122] B. Hirschel,et al. Planned interruptions of anti-HIV treatment. , 2001, The Lancet. Infectious diseases.
[123] Z. Stein. Vaginal microbicides and prevention of HIV infection , 1994, The Lancet.
[124] D. Burton,et al. GP120: target for neutralizing HIV-1 antibodies. , 2006, Annual review of immunology.
[125] M. Malim,et al. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. , 1998, Science.
[126] K. Holmes,et al. Advances in multilevel approaches to understanding the epidemiology and prevention of sexually transmitted infections and HIV: an overview. , 2005, The Journal of infectious diseases.
[127] L. Calza,et al. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. , 2003, The Journal of antimicrobial chemotherapy.
[128] F. Dabis,et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. , 2006, The Journal of infectious diseases.
[129] S. Wain-Hobson,et al. The HIV-1 clade C promoter is particularly well adapted to replication in the gut in primary infection , 2006, AIDS.
[130] D. Pérez-Caballero,et al. Restriction of Human Immunodeficiency Virus Type 1 by TRIM-CypA Occurs with Rapid Kinetics and Independently of Cytoplasmic Bodies, Ubiquitin, and Proteasome Activity , 2005, Journal of Virology.
[131] T. Quinn,et al. The Effects of Herpes Simplex Virus-2 on HIV-1 Acquisition and Transmission: A Review of Two Overlapping Epidemics , 2004, Journal of acquired immune deficiency syndromes.
[132] D. Ho,et al. HIV-1 dynamics in vivo: implications for therapy , 2003, Nature Reviews Microbiology.
[133] Cheryl Jennings,et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study , 2005, The Lancet.
[134] F. Barré-Sinoussi. HIV as the cause of AIDS , 1996, The Lancet.
[135] J. Bremer,et al. Comparison of Two Human Immunodeficiency Virus (HIV) RNA Surrogate Assays to the Standard HIV RNA Assay , 2005, Journal of Clinical Microbiology.
[136] Bhavna Chohan,et al. Evidence for Frequent Reinfection with Human Immunodeficiency Virus Type 1 of a Different Subtype , 2005, Journal of Virology.
[137] N. Saksena,et al. HIV-1 co-infection, superinfection and recombination. , 2004, Sexual health.
[138] Cott,et al. ANTIRETROVIRAL THERAPY DURING PREGNANCY AND THE RISK OF AN ADVERSE OUTCOME , 2002 .
[139] D. Trono,et al. Lentiviral vectors and antiretroviral intrinsic immunity. , 2005, Human gene therapy.
[140] B. Korber,et al. Evolutionary and immunological implications of contemporary HIV-1 variation. , 2001, British medical bulletin.
[141] R. Hayes,et al. Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials , 2000, The Lancet.
[142] H. Gershengorn,et al. A tale of two futures: HIV and antiretroviral therapy in San Francisco. , 2000, Science.
[143] R. Hogg,et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. , 1998, JAMA.
[144] B. Masquelier,et al. Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission. , 2005, AIDS research and human retroviruses.
[145] S. Deeks,et al. Treatment of antiretroviral-drug-resistant HIV-1 infection , 2003, The Lancet.
[146] J. Margolick,et al. Evaluation of a Low-Cost Method, the Guava EasyCD4 Assay, to Enumerate CD4-Positive Lymphocyte Counts in HIV-Infected Patients in the United States and Uganda , 2006, Journal of acquired immune deficiency syndromes.
[147] N. Sewankambo,et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study , 2005, The Lancet.
[148] J. Mellors,et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[149] R. Bailey,et al. Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. , 2002, The American journal of pathology.
[150] Wesley I. Sundquist,et al. Tsg101 and the Vacuolar Protein Sorting Pathway Are Essential for HIV-1 Budding , 2001, Cell.
[151] A. Woolfson,et al. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. , 2005, The Journal of antimicrobial chemotherapy.
[152] J. Blackard,et al. Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[153] N. Low,et al. Male circumcision for prevention of heterosexual acquisition of HIV in men. , 2003, The Cochrane database of systematic reviews.
[154] H. Weiss,et al. Longitudinal Assessment of HIV-1 and HSV-2 Shedding in the Genital Tract of West African Women , 2005, Journal of acquired immune deficiency syndromes.
[155] R. Walensky,et al. Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[156] Christine Katlama,et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. , 2003, The New England journal of medicine.
[157] R. König,et al. Complementary function of the two catalytic domains of APOBEC3G. , 2005, Virology.
[158] F. Förster,et al. The mechanism of HIV-1 core assembly: insights from three-dimensional reconstructions of authentic virions. , 2006, Structure.
[159] W. Greene,et al. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells , 2005, Nature.
[160] Adriano Lazzarin,et al. The Efficiency of Male‐to Female and Female‐to‐Male Sexual Transmission of the Human Immunodeficiency Virus: A Study of 730 Stable Couples , 1994, Epidemiology.
[161] R. Connor,et al. Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.
[162] N. Leidy,et al. Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection , 2006, AIDS.
[163] K. Mayer,et al. Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection. , 2006, The Journal of infectious diseases.
[164] P. Roques,et al. Phenotypic Susceptibility to Nonnucleoside Inhibitors of Virion-Associated Reverse Transcriptase From Different HIV Types and Groups , 2004, Journal of acquired immune deficiency syndromes.
[165] Paul Shinn,et al. HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.
[166] Lynn Morris,et al. Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration , 2005, PLoS medicine.
[167] P. Klotman,et al. Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection , 2006, Expert opinion on drug safety.
[168] A. Engelman,et al. A tripartite DNA-binding element, comprised of the nuclear localization signal and two AT-hook motifs, mediates the association of LEDGF/p75 with chromatin in vivo , 2006, Nucleic acids research.
[169] I. Dunham,et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. , 2002, Genomics.
[170] R. Bosch,et al. The Development and Utility of a Clinical Algorithm to Predict Early HIV-1 Infection , 2005, Journal of acquired immune deficiency syndromes.
[171] P. Foster,et al. The viral manipulation of the host cellular and immune environments to enhance propagation and survival: a focus on RNA viruses , 2002, Journal of leukocyte biology.
[172] S. Weller,et al. Condom effectiveness in reducing heterosexual HIV transmission. , 2002, The Cochrane database of systematic reviews.
[173] J. Nkengasong,et al. Integrating Prevention of Mother-to-Child HIV Transmission Into Routine Antenatal Care: The Key to Program Expansion in Cameroon , 2005, Journal of acquired immune deficiency syndromes.
[174] F. Bushman,et al. Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.
[175] I. de Vincenzi,et al. A Longitudinal Study of Human Immunodeficiency Virus Transmission by Heterosexual Partners , 1994 .
[176] R. Miksad,et al. From treatment to prevention: The interplay between HIV/AIDS treatment availability and HIV/AIDS prevention programming in Khayelitsha, South Africa , 2005, Journal of Urban Health.
[177] M. Magoni,et al. Mode of infant feeding and HIV infection in children in a program for prevention of mother-to-child transmission in Uganda , 2005, AIDS.
[178] Myron S. Cohen,et al. The role of sexually transmitted diseases in HIV transmission , 2004, Nature Reviews Microbiology.
[179] Christopher D Pilcher,et al. Amplified HIV transmission and new approaches to HIV prevention. , 2005, The Journal of infectious diseases.
[180] R. Hayes,et al. Understanding HIV Epidemic Trends in Africa , 2006, Science.
[181] M. Vray,et al. Plasma virion reverse transcriptase activity and heat dissociation-boosted p24 assay for HIV load in Burkina Faso, West Africa , 2005, AIDS.
[182] P. Price,et al. Immune restoration disease after antiretroviral therapy , 2004, AIDS.
[183] A. Wensing,et al. Worldwide transmission of drug-resistant HIV. , 2003, AIDS reviews.
[184] Richard A Lempicki,et al. HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[185] N. Hosken. Development of a therapeutic vaccine for HSV-2. , 2005, Vaccine.
[186] H. Doerr,et al. Comparative evaluation of the Cobas Amplicor HIV-1 Monitor Ultrasensitive Test, the new Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor Ultrasensitive Test and the Versant HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[187] D. Hoover,et al. Quantitative Analysis of HIV-1 Variants With the K103N Resistance Mutation After Single-Dose Nevirapine in Women With HIV-1 Subtypes A, C, and D , 2006, Journal of acquired immune deficiency syndromes.
[188] N. Davidson,et al. APOBEC3F and APOBEC3G mRNA Levels Do Not Correlate with Human Immunodeficiency Virus Type 1 Plasma Viremia or CD4+ T-Cell Count , 2006, Journal of Virology.
[189] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[190] Alan S. Perelson,et al. Increased Turnover of T Lymphocytes in HIV-1 Infection and Its Reduction by Antiretroviral Therapy , 2001, The Journal of experimental medicine.
[191] U. Abbas,et al. Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: Risk without reward , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[192] JD Lundgren,et al. Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.
[193] M. Thomson,et al. Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: an update. , 2005, AIDS reviews.
[194] Tara L. Kieffer,et al. G→A Hypermutation in Protease and Reverse Transcriptase Regions of Human Immunodeficiency Virus Type 1 Residing in Resting CD4+ T Cells In Vivo , 2005, Journal of Virology.
[195] A. Wald,et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. , 2004, The Journal of infectious diseases.
[196] D. Ho,et al. The HIV-1 Vaccine Race , 2002, Cell.
[197] John T McDevitt,et al. A Microchip CD4 Counting Method for HIV Monitoring in Resource-Poor Settings , 2005, PLoS medicine.
[198] W. Miller,et al. Trichomoniasis in men and HIV infection: data from 2 outpatient clinics at Lilongwe Central Hospital, Malawi. , 2004, The Journal of infectious diseases.
[199] P. Bieniasz,et al. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress , 2001, Nature Medicine.
[200] J. McIntyre. Strategies to prevent mother-to-child transmission of HIV , 2006, Current opinion in infectious diseases.